> Canada's Occulogix says it will file an application for an Investigational Device Exemption with the FDA for its RHEO system to treat dry age-related macular degeneration. Occulogix says it met with representatives of the FDA last week and that they asked for a new study of the RHEO System. Report
> Holly Springs, NC has been excited by reports that it is in the running for a major biopharmaceutical facility that will generate up to 400 jobs. Report
> Shares of Pozen climbed in overnight trading, recovering some of the losses triggered by an FDA request last week for more data on its migraine drug Trexima. Report
> Citing "compelling" data, Bayer HealthCare will proceed with a late-stage study of antithrombosis drug BAY 59-7939 in two chronic indications. Release
> Sunesis has snared a $4.25 million milestone payment from Merck. Release
> Ceragenix is touting preclinical results for a lead compound that demonstrates signs of inhibiting bladder cancer growth. Release
> Avigen is planning to launch a Phase IIa trial of AV411 for neuropathic pain. Release
And Finally…The mentally ill suffer from diabetes at twice the rate of the general population. Article